Delivery Order SPE2DB20D2014-SPE2DB25FB86G
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of CellCept 500 mg tablets (500-count bottles) under a firm fixed-price contract with a ceiling value of $13,051.42. The delivery order, which is not set-aside, is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100 count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $27,735.62 and carries no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $33,203.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). This competitive, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract does not carry a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $9,754.64. This firm fixed-price delivery order, issued on August 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at approximately $27,938 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) on August 25, 2025, with completion targeted for August 26, 2025. This non-set-aside, competitively awarded delivery order reflects a firm fixed-price contract structure and will be performed at the vendor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication...
- The Defense Logistics Agency awarded a delivery order valued at $12,027.50 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication used to prevent organ...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $8,966.40. This firm fixed-price delivery order, with an ultimate completion date of July 15, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CellCept 500 mg tablets (100-count packages) under a firm fixed-price contract valued at $4,349.15. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,296.81 to AmerisourceBergen Drug Corp for the supply of 100 capsules of CellCept 250 mg medication. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 9, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FB86GDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) valued at $7,854.18. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, under a firm fixed-price delivery order arrangement. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its position as a major pharmaceutical distributor and critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in organ transplant recipients and for autoimmune conditions, reflecting the diversity of pharmaceutical products delivered under this strategic contract vehicle supporting Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 5/6/25 |